title: Visceral adiposity after tibolone use.
abstract: OBJECTIVE
  To evaluate the differences in visceral fat between women using tibolone and those not using tibolone.
  
  
  METHODS
  Sixty-five healthy postmenopausal women were included in the study: 26 who were taking tibolone (2.5 mg/day); and 39 who were not receiving tibolone treatment. Anthropometric measurements were performed, with subcutaneous and visceral fat measured via ultrasound. Differences between the groups were determined via Student t test.
  
  
  RESULTS
  There were no significant differences in age (P=0.796), weight (P=0.256), height (P=0.456), body mass index (P=0.08), waist circumference (P=0.420), or waist-hip ratio (P=0.1) between the groups. Hip circumference was significantly lower in the study group than in the control group (97.7 ± 12.2 cm vs 103 ± 8.1cm; P<0.04). There were no significant differences between the groups in subcutaneous fat measurements (P=0.56). There were significantly lower visceral fat measurements (2.8 ± 1.1cm vs 3.9 ± 1.6 cm; P<0.004) and a significantly lower visceral fat-subcutaneous fat ratio (1.1 ± 0.3 vs 1.5 ± 0.7; P<0.005) in the study group than in the control group.
  
  
  CONCLUSIONS
  Postmenopausal women who use tibolone have lower visceral fat measurements than do woman of similar age who do not use tibolone.
authors.affiliation: Gynecology and Obstetrics Hospital Luis Castelazo Ayala, Social Security Mexican Institute, Mexico City, Mexico. scarranzal@mexis.com
authors.forename: Sebastián
authors.initials: S
authors.lastname: Carranza-Lira
authors.forename: Tomás D
authors.initials: TD
authors.lastname: Bárcena-Jacobo
authors.forename: Martha P
authors.initials: MP
authors.lastname: Sandoval-Barragán
authors.forename: Julio C
authors.initials: JC
authors.lastname: Ramos-León
mesh_terms: D015992:Body Mass Index; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D020847:Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D050152:Intra-Abdominal Fat / Q000187:drug effects*; D008593:Menopause; D008875:Middle Aged; D009652:Norpregnenes / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D055105:Waist Circumference
chemical_list: D020847:Estrogen Receptor Modulators; D009652:Norpregnenes; C027385:tibolone